Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment – PubMed Black Hawk Supplements

BLACK HAWK: Most trusted lions mane supplement for

Published article

BACKGROUND: Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is growing, with Alzheimer’s disease as the leading cause. There is no cure for Alzheimer’s disease, but there are regulatory-approved pharmacological interventions, such as galantamine, for symptomatic relief. This review updates the 2006 version.
Black Hawk Supplements, best supplements in the UK

Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment - PubMed

Review

. 2024 Nov 5;11(11):CD001747.

doi: 10.1002/14651858.CD001747.pub4.

Affiliations

Review

Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment

Amanda Wei Yin Lim et al. Cochrane Database Syst Rev. .

Abstract

Background: Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is growing, with Alzheimer’s disease as the leading cause. There is no cure for Alzheimer’s disease, but there are regulatory-approved pharmacological interventions, such as galantamine, for symptomatic relief. This review updates the 2006 version.

Objectives: To assess the clinical effects, including adverse effects, of galantamine in people with probable or possible Alzheimer’s disease or mild cognitive impairment, and to investigate potential moderators of effect.

Search methods: We systematically searched the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register on 14 December 2022 using the term ‘galantamine’. The Register contains records of clinical trials identified from major electronic databases (including CENTRAL, MEDLINE, and Embase), trial registries, grey literature sources, and conference proceedings. We manually searched reference lists and collected information from US Food and Drug Administration documents and unpublished trial reports. We imposed no language restrictions.

Selection criteria: We included double-blind, parallel-group, randomised controlled trials comparing oral galantamine with placebo for a treatment duration exceeding four weeks in people with dementia due to Alzheimer’s disease or with mild cognitive impairment.

Data collection and analysis: Working independently, two review authors selected studies for inclusion, assessed their quality, and extracted data. Outcomes of interest included cognitive function, change in global function, activities of daily living, functional disability, behavioural function, and adverse events. We used a fixed-effect model for meta-analytic synthesis, and presented results as Peto odds ratios (OR) or weighted mean differences (MD) with 95% confidence intervals. We used Cochrane’s original risk of bias tool (RoB 1) to assess the risk of bias in the included studies.

Main results: We included 21 studies with a total of 10,990 participants. The average age of participants was 74 years, and 37% were male. The studies’ durations ranged from eight weeks to two years, with 24 weeks being the most common duration. One newly included study assessed the effects of galantamine at two years, and another newly included study involved participants with severe Alzheimer’s disease. Nineteen studies with 10,497 participants contributed data to the meta-analysis. All studies had low to unclear risk of bias for randomisation, allocation concealment, and blinding. We judged four studies to be at high risk of bias due to attrition and two due to selective outcome reporting. Galantamine for dementia due to Alzheimer’s disease We summarise only the results for galantamine given at 8 to 12 mg twice daily (total galantamine 16 mg to 24 mg/day), assessed at six months. See the full review for results of other dosing regimens and assessment time points. There is high-certainty evidence that, compared to placebo, galantamine improves: cognitive function, as assessed with the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog) (MD-2.86, 95% CI -3.29 to -2.43; 6 studies, 3049 participants; minimum clinically important effect (MCID) = 2.6- to 4-point change); functional disability, as assessed with the Disability Assessment for Dementia (DAD) scale (MD 2.12, 95% CI 0.75 to 3.49; 3 studies, 1275 participants); and behavioural function, as assessed with the Neuropsychiatric Inventory (NPI) (MD -1.63, 95% CI -3.07 to -0.20; 2 studies, 1043 participants) at six months. Galantamine may improve global function at six months, as assessed with the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus) (OR 1.58, 95% CI 1.36 to 1.84; 6 studies, 3002 participants; low-certainty evidence). Participants who received galantamine were more likely than placebo-treated participants to discontinue prematurely (22.7% versus 17.2%) (OR 1.41, 95% CI 1.19 to 1.68; 6 studies, 3336 participants; high-certainty evidence), and experience nausea (20.9% versus 8.4%) (OR 2.89, 95% CI 2.40 to 3.49; 7 studies, 3616 participants; high-certainty evidence) during the studies. Galantamine reduced death rates at six months: 1.3% of participants in the galantamine groups had died compared to 2.3% in the placebo groups (OR 0.56, 95% CI 0.33 to 0.96; 6 studies, 3493 participants; high-certainty evidence). Galantamine for mild cognitive impairment We summarise results, assessed at two years, from two studies that gave participants galantamine at 8 to 12 mg twice daily (total galantamine 16 mg to 24 mg/day). Compared to placebo, galantamine may not improve cognitive function, as assessed with the expanded ADAS-cog for mild cognitive impairment (MD -0.21, 95% CI -0.78 to 0.37; 2 studies, 1901 participants; low-certainty evidence) or activities of daily living, assessed with the Alzheimer’s Disease Cooperative Study – Activities of Daily Living scale for mild cognitive impairment (MD 0.30, 95% CI -0.26 to 0.86; 2 studies, 1901 participants; low-certainty evidence). Participants who received galantamine were probably more likely to discontinue prematurely than placebo-treated participants (40.7% versus 28.6%) (OR 1.71, 95% CI 1.42 to 2.05; 2 studies, 2057 participants) and to experience nausea (29.4% versus 10.7%) (OR 3.49, 95% CI 2.75 to 4.44; 2 studies, 2057 participants), both with moderate-certainty evidence. Galantamine may not reduce death rates at 24 months compared to placebo (0.5% versus 0.1%) (OR 5.03, 95% CI 0.87 to 29.10; 2 studies, 2057 participants; low-certainty evidence). Results from subgroup analysis and meta-regression suggest that an imbalance in discontinuation rates between galantamine and placebo groups, together with the use of the ‘last observation carried forward’ approach to outcome assessment, may potentially bias cognitive outcomes in favour of galantamine.

Authors’ conclusions: Compared to placebo, galantamine (when given at a total dose of 16 mg to 24 mg/day) slows the decline in cognitive function, functional ability, and behaviour at six months in people with dementia due to Alzheimer’s disease. Galantamine probably also slows declines in global function at six months. The changes observed in cognition, assessed with the ADAS-cog scale, were clinically meaningful. Gastrointestinal-related adverse events are the primary concerns associated with galantamine use in people with dementia, which may limit its tolerability. Although death rates were generally low, participants in the galantamine groups had a reduced risk of death compared to those in the placebo groups. There is no evidence to support the use of galantamine in people with mild cognitive impairment.

Trial registration: ClinicalTrials.gov NCT00523666 NCT00679627 NCT00216593 NCT00253214 NCT00236431 NCT00236574 NCT00253227 NCT00261573 NCT00814801 NCT01362686 NCT00309725 NCT01969136 NCT01921972 NCT00304629.

PubMed Disclaimer

Conflict of interest statement

Amanda Wei‐Yin Lim: none known

Lon Schneider: works at the University of Southern California, USC; has received funds for research from Biogen, Eli Lilly, Merck, Novartis, Roche/Genentech, and TauRx; has received consultancy fees from Alpha‐cognition and Corium.

Clement Loy: none known

Update of

  • doi: 10.1002/14651858.CD001747.pub3

Similar articles

References

References to studies included in this review

Blautzik 2016 {published data only}
    1. Blautzik J, Keeser D, Paolini M, Kirsch V, Berman A, Coates U, et al. Functional connectivity increase in the default-mode network of patients with Alzheimer’s disease after long-term treatment with galantamine. European Neuropsychopharmacology 2016;26(3):602-13. [DOI: 10.1016/j.euroneuro.2015.12.006] [PMID: ] – DOI – PubMed
    1. Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, et al. Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. European Archives of Psychiatry and Clinical Neuroscience 2012;262(4):341-50. [DOI: 10.1007/s00406-011-0234-2] [PMID: ] – DOI – PubMed
    1. NCT00523666. Diffusion tensor weighted MRI in Alzheimer’s disease modifying treatment effects of galantamine (Reminyl®). clinicaltrials.gov/ct2/show/NCT00523666 (first posted: 31 August 2007).
GAL‐93‐01 Wilkinson 2001 {published and unpublished data}
    1. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled, study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer’s type. Neurobiology of Aging 1996;17(4 Suppl 1):S144.
    1. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry 2001;16(9):852-7. [DOI: 10.1002/gps.409] [PMID: ] – DOI – PubMed
GAL‐95‐05 1999 {unpublished data only}
    1. Kristensen M, Richardson A, Van Osselaer N, Vangeneugden T, Morrison S, Fleet D, et al. A European multicentre placebo-controlled trial to determine the safety and efficacy of galantamine hydrobromide 40 mg/day (32 mg/day GAL base, tid dose regimen) in patients diagnosed with Alzheimer-type dementia. Janssen Research Foundation Clinical Research Report Trial GAL-95-05 (report date: February 1999).
GALALZ3005 Hager 2014 {published and unpublished data}
    1. EUCTR2007-002780-27-AT. A randomized, double-blind, placebo-controlled trial of long-term (2-year) treatment of galantamine in mild to moderately-severe Alzheimer’s disease. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-00… (first received 11 September 2007).
    1. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]. Neuropsychiatric Disease and Treatment 2014;10:1997. [DOI: 10.2147/NDT.S71540] – DOI – PMC – PubMed
    1. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]. Neuropsychiatric Disease and Treatment 2014;10:1997. [DOI: 10.2147/NDT.S71540] – DOI – PMC – PubMed
    1. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatric Disease and Treatment 2014;10:391-401. [DOI: 10.2147/NDT.S57909] [PMID: ] – DOI – PMC – PubMed
    1. NCT00679627. A study of galantamine used to treat patients with mild to moderate Alzheimer’s disease. clinicaltrials.gov/ct2/show/NCT00679627 (first received 15 May 2008). [CENTRAL: CN-00714072]
GAL‐ALZ‐302 Burns 2009 {published and unpublished data}
    1. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD) study: a randomised, placebo-controlled, double-blind trial. Lancet Neurology 2009;8(1):39-47. [DOI: 10.1016/S1474-4422(08)70261-8] [PMID: ] – DOI – PubMed
    1. Burns A. Treatment of severe Alzheimer’s disease in a residential home, nursing home, or geriatric residence setting: evaluation of efficacy and safety of galantamine (Reminyl®) in a randomised, double-blind, placebo-controlled study. yoda.yale.edu/sites/default/files/nct00216593.pdf 2008.
    1. NCT00216593. Treatment of severe Alzheimer’s disease: evaluation of efficacy and safety of galantamine hydrobromide in a controlled study. clinicaltrials.gov/ct2/show/record/NCT00216593 (first posted: 22 September 2005).
GAL‐INT‐10 Brodaty 2005 {published and unpublished data}
    1. Brodaty H (coordinating investigator). Placebo-controlled evaluation of galantamine in the treatment of Alzheimer’s disease: safety and efficacy of a controlled-release formulation. Johnson & Johnson Pharmaceutical Research & Development, L.L.C (report date: 31 January 2003).
    1. Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2005;20(2-3):120-32. [DOI: 10.1159/000086613] [PMID: ] – DOI – PubMed
    1. NCT00253214. Placebo-controlled evaluation of galantamine in the treatment of Alzheimer’s disease: safety and efficacy of a controlled-release formulation. clinicaltrials.gov/ct2/show/record/NCT00253214 (first posted: 15 November 2005).
GAL‐INT‐11 DeKosky 2008 {published and unpublished data}
    1. DeKosky S (coordinating investigator). A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer’s disease. yoda.yale.edu/sites/default/files/nct00236574.pdf 2004.
    1. NCT00236431. A study to evaluate the efficacy and safety of galantamine in patients with mild cognitive impairment. clinicaltrials.gov/ct2/show/NCT00236431 (first posted: 12 October 2005).
    1. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70(22):2024-35. [DOI: 10.1212/01.wnl.0000303815.69777.26] [PMID: ] – DOI – PubMed
GAL‐INT‐18 Winblad 2008 {published and unpublished data}
    1. NCT00236431. A study to evaluate the efficacy and safety of galantamine in patients with mild cognitive impairment. clinicaltrials.gov/ct2/show/NCT00236431 (first posted: 12 October 2005).
    1. Winblad B (coordinating investigator). A randomized double-blind, placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer’s disease. yoda.yale.edu/sites/default/files/nct00236431.pdf 2004.
    1. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70(22):2024-35. [DOI: 10.1212/01.wnl.0000303815.69777.26] [PMID: ] – DOI – PubMed
GAL‐INT‐1 Wilcock 2000 {published data only}
    1. GAL-INT-3. Long-term safety and efficacy of galantamine in the treatment of Alzheimer’s disease. yoda.yale.edu/sites/default/files/gal-int-3.pdf (first received June 1999).
    1. Wilcock GK, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000;321(7274):1445-9. [DOI: 10.1136/bmj.321.7274.1445] [PMID: ] – DOI – PMC – PubMed
    1. Wilcock GK, Lilienfeld S. Galantamine alleviates caregiver burden in Alzheimer’s disease: a 6-month placebo-controlled study. In: Conference Proceedings World Alzheimer Congress; 9-13 July, 2000, Washington. 2000.
    1. Wilcock GK. Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2001;322(7283):405. – PMC – PubMed
GAL‐INT‐2 Rockwood 2001 {published and unpublished data}
    1. NCT00253227. A study of the safety and effectiveness of a flexible dose of galantamine versus placebo in the treatment of patients with Alzheimer’s disease. clinicaltrials.gov/ct2/show/NCT00253227 (first posted: 15 November 2005).
    1. NCT00304629. Long-term safety and efficacy of galantamine in the treatment of Alzheimer’s disease. clinicaltrials.gov/ct2/show/NCT00304629 (first received 20 March 2006).
    1. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer’s disease taking galantamine for up to 48 months. International Journal of Geriatric Psychiatry 2008;23(2):207-14. [DOI: 10.1002/gps.1864] [PMID: ] – DOI – PubMed
    1. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D, Galantamine International-2 Study Group. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. Journal of Neurology, Neurosurgery & Psychiatry 2001;71(5):589-95. [DOI: 10.1136/jnnp.71.5.589] [PMID: ] – DOI – PMC – PubMed
    1. VIV00004683. IPD data package for study ‘galantamine in the treatment of Alzheimer’s disease: flexible dose range trial’ and research request: ‘meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies’. https://vivli.org/meta-analysis-of-efficacy-of-cholinesterase-inhibitors…. [DOI: 10.25934/00004683] [Vivli ID: VIV00004683] – DOI
GAL‐INT‐6 Erkinjuntti 2002 {published and unpublished data}
    1. Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group. Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine. Dementia and Geriatric Cognitive Disorders 2004;17(1-2):29-34. [DOI: 10.1159/000074140] [PMID: ] – DOI – PubMed
    1. Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, et al. Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). Journal of Psychopharmacology 2008;22(7):761-8. [DOI: 10.1177/0269881107083028] [PMID: ] – DOI – PubMed
    1. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359(9314):1283-90. [DOI: 10.1016/S0140-6736(02)08267-3] [PMID: ] – DOI – PubMed
    1. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. The safety and efficacy of galantamine in the treatment of vascular and mixed dementia (double-blind part only). yoda.yale.edu/sites/default/files/nct00261573.pdf 2004.
    1. Erkinjuntti T. Treatment options: the latest evidence with galantamine (Reminyl®). Journal of the Neurological Sciences 2002;203-204:125-30. [DOI: 10.1016/S0022-510X(02)00267-8] – DOI – PubMed
GAL‐USA‐10 Tariot 2000 {published data only}
    1. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. American Journal of Geriatric Psychiatry 2004;12(5):473-82. [DOI: 10.1176/appi.ajgp.12.5.473] [PMID: ] – DOI – PubMed
    1. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galamtine in AD. Neurology 2000;54(12):2269-76. [DOI: 10.1212/WNL.54.12.2269] [PMID: ] – DOI – PubMed
GAL‐USA‐1 Raskind 2000 {published data only}
    1. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurology 2004;61(2):252-6. [DOI: 10.1001/archneur.61.2.252] [PMID: ] – DOI – PubMed
    1. Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54(12):2261-8. [DOI: 10.1212/WNL.54.12.2261] [PMID: ] – DOI – PubMed
Kadir 2008 {published data only}
    1. Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiology of Aging 2008;29(2):168-84. [CENTRAL: CN-00617596] [DOI: 10.1016/j.neurobiolaging.2006.09.020] [PMID: ] – DOI – PubMed
    1. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiology of Aging 2008;29(8):1204-17. [DOI: 10.1016/j.neurobiolaging.2007.02.020] [PMID: ] – DOI – PubMed
    1. Keller C, Kadir A, Forsberg A, Porras O, Nordberg A. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer’s disease patients. Journal of Alzheimer’s Disease 2011;24(11):109-23. [DOI: 10.3233/JAD-2010-101290] [PMID: ] – DOI – PubMed
Kewitz 1994b {published data only}
    1. Kewitz H, Berzewski H, Rainer M, Dal-Bianco P, Friedl E, Deisenhammer J, et al. Galantamine, a selective non-toxic acetylcholinesterase inhibitor is significantly superior over placebo in treatment of SDAT. Neuropsychopharmacology 1994;10(3S):130S.
Koontz 2005 {published data only}
    1. Koontz K, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. American Journal of Alzheimer’s Disease and Other Dementias 2005;20(5):295-302. [DOI: 10.1177/153331750502000502] [PMID: ] – DOI – PMC – PubMed
Liu 2003 {published data only}
    1. Liu F, Gao Z, Chen M, Ma Y, Shao F, Zhang G, et al. Evaluation of galantamine in treatment of Alzheimer’s disease: a multicentre, randomized, double-blind study. [Chinese Journal of New Drugs and Clinical Remedies] 2003;22(1):29-32.
Rockwood 2006 {published data only}
    1. Hamilton L, Fay S, Rockwood K. Misplacing objects in mild to moderate Alzheimer’s disease: a descriptive analysis from the VISTA clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry 2009;80(9):960-5. [CENTRAL: CN-00721751] [DOI: 10.1136/jnnp.2008.166801] [PMID: ] – DOI – PubMed
    1. ISRCTN26167328. The Video Imaging Synthesis of Treating Alzheimer’s disease study. isrctn.com/ISRCTN26167328 (first received 1 September 2005).
    1. Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer’s disease. International Journal of Geriatric Psychiatry 2010;25(2):191-201. [DOI: 10.1002/gps.2319] [PMID: ] – DOI – PubMed
    1. Rockwood K, Fay S, Song X, MacKnight C, Gorman M, Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ 2006;174(8):1099-105. [DOI: 10.1503/cmaj.051432] [PMID: ] – DOI – PMC – PubMed
    1. Rockwood K, Howlett SE, Hoffman D, Schindler R, Mitnitski A. Clinical meaningfulness of Alzheimer’s Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. Alzheimer’s & Dementia 2017;13(10):1098-106. [DOI: 10.1016/j.jalz.2017.02.005] – DOI – PubMed
Xie 2003 {published data only}
    1. Xie S, Ma Y, Zhu X, Wu S, Liu F, Yang J, et al. Galantamine in treating age-associated memory impairment and Alzheimer’s disease by double blind method. [Geriatric Health Care] 2003;9(4):223-6.

References to studies excluded from this review

Aronson 2009 {published data only}
    1. Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of galantamine in patients with mild or moderate Alzheimer’s disease: post hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs & Aging 2009;26(3):231-9. [DOI: 10.2165/00002512-200926030-00004] [PMID: ] – DOI – PubMed
Campbell 2015 {published and unpublished data}
    1. Campbell N, Perkins A, Boustani M. A randomized trial of the adherence and tolerability of acetylcholinesterase inhibitors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2015;11(7):P901 (P4-303). [DOI: 10.1016/j.jalz.2015.08.133] – DOI
    1. Campbell NL, Perkins AJ, Gao S, Skaar TC, Li L, Hendrie HC, et al. Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial. Journal of the American Geriatrics Society 2017;65(7):1497-1504. [10.1111/jgs.14827] [PMID: ] – PMC – PubMed
Caramelli 2014 {published data only}
    1. Caramelli P, Laks J, Palmini AL, Nitrini R, Chaves ML, Forlenza OV, et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arquivos de Neuro-Psiquiatria 2014;72(6):411-7. [DOI: 10.1590/0004-282X20140055] [PMID: ] – DOI – PubMed
Cook 2008 {published data only}
    1. Cook C, Fay S, Rockwood K. Decreased initiation of usual activities in people with mild-to-moderate Alzheimer’s disease: a descriptive analysis from the VISTA clinical trial. International Psychogeriatrics 2008;20(5):952-63. [CENTRAL: CN-00648088] [DOI: 10.1017/S1041610208007230] [PMID: ] – DOI – PubMed
Cook 2009 {published data only}
    1. Cook C, Fay S, Rockwood K. Verbal repetition in people with mild-to-moderate Alzheimer disease: a descriptive analysis from the VISTA clinical trial. Alzheimer Disease and Associated Disorders 2009;23(2):146-51. [DOI: 10.1097/WAD.0b013e318193cbef] [PMID: ] – DOI – PubMed
Dunbar 2006 {published data only}
    1. Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clinical Therapeutics 2006;28(3):365-72. [DOI: 10.1016/j.clinthera.2006.03.002] [PMID: ] – DOI – PubMed
Engedal 2012 {published data only}
    1. Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N. Two galantamine titration regimens in patients switched from donepezil. Acta Neurologica Scandinavica 2012;126(1):37-44. [DOI: 10.1111/j.1600-0404.2011.01594.x] [PMID: ] – DOI – PubMed
Freund‐Levi 2014 {published data only}
    1. Freund-Levi Y, Bloniecki V, Auestad B, Tysen Bäckström AC, Lärksäter M, Aarsland D. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dementia and Geriatric Cognitive Disorders 2014;38(3-4):234-44. [DOI: 10.1159/000362204] [PMID: ] – DOI – PubMed
Guzman‐Martinez 2021 {published data only}
    1. Guzman-Martinez L, Farías GA, Tapia JP, Sánchez MP, Fuentes P, Gloger S, et al. Interventional study to evaluate the clinical effects and safety of the nutraceutical compound BrainUp-10® in a cohort of patients with Alzheimer’s disease: a multicenter, randomized, double-blind, and placebo-controlled trial. Journal of Alzheimer’s Disease 2021;81(3):1231-41. [DOI: 10.3233/JAD-201501] – DOI – PubMed
Hager 2016 {published data only}
    1. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. Additional file 8. Alzheimer’s Research & Therapy 2016;8(1):47. 22644427 [DOI: 10.1186/s13195-016-0214-x] [PMID: ] – DOI – PMC – PubMed
    1. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer’s Research & Therapy 2016;8(1):47. [DOI: 10.1186/s13195-016-0214-x] [PMID: ] – DOI – PMC – PubMed
Hannestad 2021 {published data only}
    1. Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, et al. Safety and tolerability of GRF6019 infusions in severe Alzheimer’s disease: a phase II double-blind placebo-controlled trial. Journal of Alzheimer’s Disease 2021;81(4):1649-62. [DOI: 10.3233/JAD-210011] – DOI – PubMed
Iosifescu 2016 {published data only}
    1. Iosifescu DV, Murrough JW, Deckersbach T, Parides M, Iacoviello B, Nierenberg AA. Galantamine-ER for cognitive deficits in bipolar disorder. Biological Psychiatry 2016;79(9):S1-438 (Abstract No. 177).
Litvinenko 2008 {published data only}
    1. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (Reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neuroscience and Behavioral Physiology 2008;38(9):937-45. [CENTRAL: CN-00684474] [DOI: 10.1007/s11055-008-9077-3] [PMID: ] – DOI – PubMed
NCT00309725 {unpublished data only}
    1. NCT00309725. A cardiac safety of galantamine in the treatment of Alzheimer’s disease. clinicaltrials.gov/ct2/show/NCT00309725 (first received 3 April 2006). [CR012118]
NCT01969136 {unpublished data only}
    1. NCT01969136. Study of the safety and effectiveness of two doses of investigational study drug EVP-6124 in subjects with Alzheimer’s disease. clinicaltrials.gov/ct2/show/NCT01969136 (first received 25 October 2013).
Nordberg 2009 {published data only}
    1. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer Research 2009;6(1):4-14. [CENTRAL: CN-00683735] [DOI: 10.2174/156720509787313961] [PMID: ] – DOI – PMC – PubMed
Ohnishi 2014 {published data only}
    1. Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, et al. The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease. Current Alzheimer Research 2014;11(2):110-8. [DOI: 10.2174/15672050113106660167] [PMID: ] – DOI – PMC – PubMed
Orgogozo 2004 {published data only}
    1. Orgogozo JM, Small GW, Hammond G, Van Baelen B, Schwalen S. Effects of galantamine in patients with mild Alzheimer’s disease. Current Medical Research and Opinion 2004;20(11):1815-20. [DOI: 10.1185/030079904X12555] [PMID: ] – DOI – PubMed
Parnetti 2011 {published data only}
    1. Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, et al. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease. Acta Neurologica Scandinavica 2011;124(2):122-9. [DOI: 10.1111/j.1600-0404.2010.01435.x] [PMID: ] – DOI – PubMed
Peters 2012 {published data only}
    1. Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. Journal of Nutrition, Health & Aging 2012;16(6):544-8. [DOI: 10.1007/s12603-012-0062-8] [PMID: ] – DOI – PubMed
Peters 2015 {published data only}
    1. Peters O, Fuentes M, Joachim LK, Jessen F, Luckhaus C, Kornhuber J, et al. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer’s disease. Alzheimer’s & Dementia 2015;1(3):198-204. [DOI: 10.1016/j.trci.2015.10.001] [PMID: ] – DOI – PMC – PubMed
Pirttila 2004 {published data only}
    1. Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicenter trial. European Journal of Neurology 2004;11(11):734-41. [DOI: 10.1111/j.1468-1331.2004.00885.x] [PMID: ] – DOI – PubMed
Prins 2014 {published data only}
    1. Prins ND, Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer’s Research & Therapy 2014;6(4):47. [DOI: 10.1186/alzrt275] [PMID: ] – DOI – PMC – PubMed
Richarz 2011 {published data only}
    1. Richarz U, Engedal K, Davis B, Gaudig M, Han J, Schaeuble B. Efficacy and tolerability of two galantamine titration regimens in patients switched from donepezil. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2011;7(4):S800 (P4-268). [DOI: 10.1016/j.jalz.2011.05.2305] – DOI
Rockwood 2008 {published data only}
    1. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer’s disease taking galantamine for up to 48 months. International Journal of Geriatric Psychiatry 2008;23(2):207-14. [DOI: 10.1002/gps.1864] [PMID: ] – DOI – PubMed
Turner 2020 {published data only}
    1. Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Annals of Neurology 2020;88(1):183-94. [DOI: 10.1002/ana.25775] [PMID: ] – DOI – PMC – PubMed
Vellas 2011 {published data only}
    1. Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, et al. EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study. Current Alzheimer Research 2011;8(2):203-12. [DOI: 10.2174/156720511795256053] [PMID: ] – DOI – PubMed
Vila‐Castelar 2019 {published data only}
    1. Vila-Castelar C, Ly JJ, Kaplan L, Van Dyk K, Berger JT, Macina LO, et al. Attention measures of accuracy, variability, and fatigue detect early response to donepezil in Alzheimer’s disease: a randomized, double-blind, placebo-controlled pilot trial. Archives of Clinical Neuropsychology 2019;34(3):277-89. [DOI: 10.1093/arclin/acy032] – DOI – PMC – PubMed
Voss 2018 {published data only}
    1. Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer’s disease. Alzheimer’s and Dementia: Translational Research and Clinical Interventions 2018;4:173-81. [DOI: 10.1016/j.trci.2018.03.004] – DOI – PMC – PubMed
Wouters 2010 {published data only}
    1. Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL. Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands. Tijdschrift voor Gerontologie en Geriatrie 2010;41(3):146-50. [CENTRAL: CN-00749350] [PMID: ] – PubMed
Youn 2021 {published data only}
    1. Youn H, Lee KJ, Kim SG, Cho SJ, Kim WJ, Lee WJ, et al. The behavioral effects of combination therapy of memantine and acetylcholinesterase inhibitors compared with acetylcholinesterase inhibitors alone in patients with moderate Alzheimer’s dementia: a double-blind randomized placebo-controlled trial. Psychiatry Investigation 2021;18(3):233-40. [DOI: 10.30773/pi.2020.0329] – DOI – PMC – PubMed
Zhang 2012 {published data only}
    1. Zhang Z, Yu L, Gaudig M, Schäuble B, Richarz U. Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study. Neuropsychiatric Disease and Treatment 2012;8:571-7. [DOI: 10.2147/NDT.S38747] [PMID: ] – DOI – PMC – PubMed

Additional references

Albuquerque 2001
    1. Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Disease and Associated Disorders 2001;15 Suppl 1:S19-25. [PMID: ] – PubMed
Alzheimer’s Association 2021
    1. Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 2021;17(3):327-406. [DOI: 10.1002/alz.12328] [PMID: ] – DOI – PubMed
Andrews 2019
    1. Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimer’s & Dementia 2019;5:354-63. [DOI: 10.1016/j.trci.2019.06.005] [PMID: ] – DOI – PMC – PubMed
APA 1987
    1. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders: DSM IIIR. 3rd revised edition. Washington, DC: American Psychiatric Association, 1987.
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [DOI: 10.1016/j.jclinepi.2010.07.015] [PMID: ] – DOI – PubMed
Battle 2021
    1. Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database of Systematic Reviews 2021;2(2):CD013306. [DOI: 10.1002/14651858.CD013306.pub2] [PMID: ] – DOI – PMC – PubMed
Bertilsson 1995
    1. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics 1995;29(3):192-209. [DOI: 10.2165/00003088-199529030-00005] [PMID: ] – DOI – PubMed
Bullock 2004a
    1. Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group. Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-month treatment with galantamine. Dementia and Geriatric Cognitive Disorders 2004;17(1-2):29-34. [DOI: 10.1159/000074140] [PMID: ] – DOI – PubMed
Cummings 1994
    1. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14. [PMID: ] – PubMed
Cummings 2019
    1. Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer’s Disease: current and future pharmacotherapy options. Journal of Alzheimer’s Disease 2019;67(3):779-94. [DOI: 10.3233/JAD-180766] [PMID: ] – DOI – PMC – PubMed
Deeks 2023
    1. Deeks JJ, Higgins JP, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.
Di Santo 2013
    1. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. Journal of Alzheimer’s Disease 2013;35(2):349-61. [DOI: 10.3233/JAD-122140] [PMID: ] – DOI – PubMed
Dodge 2012
    1. Dodge HH, Buracchio TJ, Fisher GG, Kiyohara Y, Meguro K, Tanizaki Y, et al. Trends in the prevalence of dementia in Japan. International Journal of Alzheimer’s Disease 2012;2012:956354. [DOI: 10.1155/2012/956354] [PMID: ] – DOI – PMC – PubMed
EBCTCG 1990
    1. Early Breast Cancer Trialists’ Collaborative Group. Treatment of Early Breast Cancer: Worldwide Evidence, 1985-1990. Oxford, UK: Oxford University Press, 1990.
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629] [PMID: ] – DOI – PMC – PubMed
FDA 1989
    1. Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville, MD: Department of Health and Human Services, Public Health Service 1989:227.
Folstein 1975
    1. Folstein MF, Folstein SE, McHugh PR. “Mini‐mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98. [DOI: 10.1016/0022-3956(75)90026-6] [PMID: ] – DOI – PubMed
Galasko 1997
    1. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S33-9. [DOI: 10.1097/00002093-199700112-00005] [PMID: ] – DOI – PubMed
Gelinas 1999
    1. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. American Journal of Occupational Therapy 1999;53(5):471-81. [DOI: 10.5014/ajot.53.5.471] [PMID: ] – DOI – PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [DOI: 10.1136/bmj.39489.470347.AD] [PMID: ] – DOI – PMC – PubMed
Hansen 2008
    1. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clinical Interventions in Aging 2008;3(2):211-25. [PMID: ] – PMC – PubMed
Higgins 2011a
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Higgins 2011b
    1. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Higgins 2023
    1. Higgins JP, Li T, Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Howard 2011
    1. Howard R, Phillips P, Johnson T, O’Brien J, Sheehan B, Lindesay J, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry 2011;26(8):812-7. [DOI: 10.1002/gps.2607] [PMID: ] – DOI – PubMed
Kaduszkiewicz 2005
    1. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005;331(7512):321-7. [DOI: 10.1136/bmj.331.7512.321] [PMID: ] – DOI – PMC – PubMed
Kavanagh 2011
    1. Kavanagh S, Howe I, Brashear HR, Wang D, Baelen B, Todd M, et al. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer’s disease. Current Alzheimer Research 2011;8(2):175-86. [DOI: 10.2174/156720511795256044] [PMID: ] – DOI – PMC – PubMed
Keller 2011
    1. Keller C, Kadir A, Forsberg A, Porras O, Nordberg A. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer’s disease patients. Journal of Alzheimer’s Disease 2011;24(11):109-23. [DOI: 10.3233/JAD-2010-101290] [PMID: ] – DOI – PubMed
Kocahan 2017
    1. Kocahan S, Doğan Z. Mechanisms of Alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clinical Psychopharmacology and Neuroscience 2017;15(1):1-8. [DOI: 10.9758/cpn.2017.15.1.1] [PMID: ] – DOI – PMC – PubMed
Lanctôt 2003
    1. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ 2003;169(6):557-64. [PMID: ] – PMC – PubMed
Li 2022
    1. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Frontiers in Aging Neuroscience 2022;14:937486. [DOI: 10.3389/fnagi.2022.937486] [PMID: ] – DOI – PMC – PubMed
Likitjaroen 2012
    1. Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, et al. Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. European Archives of Psychiatry and Clinical Neuroscience 2012;262(4):341-50. [DOI: 10.1007/s00406-011-0234-2] [PMID: ] – DOI – PubMed
Lin 1991
    1. Lin KM, Poland RE, Smith MW, Strickland TL, Mendoza R. Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacology Bulletin 1991;27(4):427-39. [PMID: ] – PubMed
McGleenon 1999
    1. McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. British Journal of Clinical Pharmacology 1999;48(4):471-80. [DOI: 10.1046/j.1365-2125.1999.00026.x] [PMID: ] – DOI – PMC – PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34(7):939-44. [PMID: ] – PubMed
Mohs 1997
    1. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11 Suppl 2:S13-21. [PMID: ] – PubMed
Molnar 2009
    1. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Medicine 2009;3(2):e31-50. [PMID: ] – PMC – PubMed
Morris 1993
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412-4. [DOI: 10.1212/wnl.43.11.2412-a] [PMID: ] – DOI – PubMed
Muir 2024
    1. Muir RT, Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer’s disease: rapid review. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2024;20(5):3352-63. [DOI: 10.1002/alz.13770] [PMID: ] – DOI – PMC – PubMed
Nich 2002
    1. Nich C, Carroll KM. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug and Alcohol Dependence 2002;68(2):121-30. [DOI: 10.1016/S0376-8716(02)00111-4] [PMID: ] – DOI – PMC – PubMed
Ohara 2017
    1. Ohara T, Hata J, Yoshida D, Mukai N, Nagata M, Iwaki T, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology 2017;88(20):1925-32. [DOI: 10.1212/WNL.0000000000003932] [PMID: ] – DOI – PubMed
Oremus 2010
    1. Oremus M, Santaguida P, Raina P. Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia. Clinical Medicine Insights: Therapeutics 2010;2:CMT.S5884.
Parsons 2013
    1. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotoxicity Research 2013;24(3):358-69. [DOI: 10.1007/s12640-013-9398-z] [PMID: ] – DOI – PMC – PubMed
Parsons 2021
    1. Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews 2021;2(2):CD009081. [DOI: 10.1002/14651858.CD009081.pub2] [PMID: ] – DOI – PMC – PubMed
Pohanka 2011
    1. Pohanka M. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. International Journal of Molecular Sciences 2014;15(6):9809-25. [DOI: 10.3390/ijms15069809] [PMID: ] – DOI – PMC – PubMed
Prakash 2008
    1. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. International Journal of Clinical Practice 2008;62(8):1147-58. [DOI: 10.1111/j.1742-1241.2008.01808.x] [PMID: ] – DOI – PMC – PubMed
Probstfield 1995
    1. Probstfield J, Applegate WB. Prospective meta-analysis: ahoy! A clinical trial? Journal of the American Geriatrics Society 1995;43(4):452-3. [DOI: 10.1111/j.1532-5415.1995.tb05823.x] [PMID: ] – DOI – PubMed
Reitz 2014
    1. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical Pharmacology 2014;88(4):640-51. [DOI: 10.1016/j.bcp.2013.12.024] [PMID: ] – DOI – PMC – PubMed
Review Manager 2024 [Computer program]
    1. Review Manager (RevMan). Version Version 8.1.1. The Cochrane Collaboration, 2024, 2024. Available at revman.cochrane.org.
Rockwood 2010
    1. Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer’s disease. International Journal of Geriatric Psychiatry 2010;25(2):191-201. [DOI: 10.1002/gps.2319] [PMID: ] – DOI – PubMed
Rosen 1984
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. American Journal of Psychiatry 1984;141(11):1356-64. [DOI: 10.1176/ajp.141.11.1356] [PMID: ] – DOI – PubMed
Schneider 1997
    1. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer’s Disease and Associated Disorders 1997;11 Suppl 2:S22-32. [DOI: 10.1007/978-1-4612-4116-4_64] [PMID: ] – DOI – PubMed
Schrag 2012
    1. Schrag A, Schott JM, Alzheimer’s Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS-Cog? Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(2):171-3. [DOI: 10.1136/jnnp-2011-300881] [PMID: ] – DOI – PubMed
Stata [Computer program]
    1. Stata. Version 13. College Station, TX, USA: StataCorp, 2013. Available at www.stata.com.
Tabet 2006
    1. Tabet N. Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing! Age and Ageing 2006;35(4):336-8. [DOI: 10.1093/ageing/afl027] [16788077] – DOI – PubMed
Takeda 2006
    1. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. International Journal of Geriatric Psychiatry 2006;21(1):17-28. [DOI: 10.1002/gps.1402] [PMID: ] – DOI – PubMed
Thomas 2024
    1. Thomas J, Askie LM, Berlin JA, Elliott JH, Ghersi D, Simmonds M, et al. Chapter 22: Prospective approaches to accumulating evidence [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Thomsen 1990
    1. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Annals of Pharmacotherapy 2007;41(9):1411-26. [DOI: 10.1345/aph.1H658] [PMID: ] – DOI – PubMed
Turok 2011
    1. Turok DK, Espey E, Edelman AB, Lotke PS, Lathrop EH, Teal SB, et al. The methodology for developing a prospective meta-analysis in the family planning community. Trials 2011;12:104. [DOI: 10.1186/1745-6215-12-104] [PMID: ] – DOI – PMC – PubMed
Watt 2021
    1. Watt JA, Veroniki AA, Tricco AC, Straus SE. Using a distribution-based approach and systematic review methods to derive minimum clinically important differences. BMC Medical Research Methodology 2021;21(1):41. [DOI: 10.1186/s12874-021-01228-7] [PMID: ] – DOI – PMC – PubMed
Wessler 2008
    1. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. British Journal of Pharmacology 2008;154(8):1558-71. [DOI: 10.1038/bjp.2008.185] [PMID: ] – DOI – PMC – PubMed
Wilkinson 2004
    1. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs & Aging 2004;21(7):453-78. [PMID: ] – PubMed
Winblad 2008
    1. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70(22):2024-35. [DOI: 10.1212/01.wnl.0000303815.69777.26] [PMID: ] – DOI – PubMed
Zhang 2016
    1. Zhang X, Shao J, Wei Y, Zhang H. Efficacy of galantamine in treatment of Alzheimer’s disease: an update meta-analysis. International Journal of Clinical and Experimental Medicine 2016;9(4):7423-30. [ISSN: 1940-5901/IJCEM0020979]
Čolović 2013
    1. Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current Neuropharmacology 2013;11(3):315-35. [DOI: 10.2174/1570159X11311030006] [PMID: ] – DOI – PMC – PubMed

References to other published versions of this review

Loy 2004
    1. Loy C, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No: CD001747. [DOI: 10.1002/14651858.CD001747.pub3] [PMID: ] – DOI – PubMed
Loy 2006
    1. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No: CD001747. [DOI: 10.1002/14651858.CD001747.pub3] [PMID: ] – DOI – PMC – PubMed
Olin 2002
    1. Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD001747. [DOI: 10.1002/14651858.CD001747] [PMID: ] – DOI – PubMed

Publication types

MeSH terms

Substances

BLACK HAWK: Best ashwagandha supplement for women

Read the original publication:

Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment – PubMed